Proliferative Vitreoretinopathy - Pipeline Review, H2 2016; New Report Launched

Proliferative Vitreoretinopathy (PVR) pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. Proliferative Vitreoretinopathy (PVR) – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proliferative Vitreoretinopathy (PVR) Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes.   The molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. Driven by data built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

For more information Visit at: http://mrr.cm/3Sj

Related Reports;

Seasonal Allergic Rhinitis - Pipeline Review, H2 2016 - Visit at - http://mrr.cm/3S9

Sleep Apnea - Pipeline Review, H2 2016 - Visit at - http://mrr.cm/3SC

Nicotine Addiction - Pipeline Review, H2 2016 - Visit at - http://mrr.cm/3Sy

Chemotherapy Induced Anemia - Pipeline Review, H2 2016 - Visit at - http://mrr.cm/3SF